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cients included: age, poverty status, total number of 
prescriptions, and total out-of-pocket non-prescription
health care costs. Signiﬁcant predictors with negative
coefﬁcients included: education, race/ethnicity, covered
prescription costs and percent of prescription drug expen-
ditures for generic drugs. The overall model was signiﬁ-
cant (p < 0.001) with an R2 = 0.44.
CONCLUSIONS: Out-of-pocket prescription drug costs
were associated with several sociodemographic and
health care cost variables. However, no signiﬁcant asso-
ciations were found between health status and perceived
access to care variables. These ﬁndings suggest that eco-
nomic factors are important when assessing out-of-pocket
expenditures but other variables such as prescription drug
characteristics should not be omitted.
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OBJECTIVE: Healthcare utilization during the last year
of life has traditionally comprised 27% to 31% of the
total Medicare budget, but knowledge of factors affect-
ing terminal costs is limited. We examined the effects of
age, gender, ethnicity, and chronic illness on medical costs
in the last year of life.
METHODS: This was a retrospective cohort analysis of
longitudinal utilization data in a regional health mainte-
nance organization (HMO). Study subjects were HMO
members (2312) who died between January 1, 1996 and
December 31, 1998. Healthcare utilization during the 12
months prior to death was captured from administrative
claims and matched to cause of death on the death 
certiﬁcate. We also determined chronic illnesses present
using claims data and compared this to cause of death on
the death certiﬁcate.
RESULTS: Mean total cost in the last year of life was
$37,736 (+$21,692), with two-thirds of the costs attrib-
uted to inpatient care ($23,321 +$8,748) per patient).
Costs varied widely by age at time of death, with mean
total costs highest among persons age 65 to 70. Costs fell
rapidly after age 70. Total costs increased linearly with
the number of chronic illnesses, which varied signiﬁcantly
with age. Patients with renal failure and complicated 
diabetes had terminal costs substantially higher than 
did patients with most other chronic illnesses; costs for
patients who died with chronic dementia were lower than
average. Sex and ethnicity were not signiﬁcant factors
after adjustment for age. Cost analyses based on the cause
of death on death certiﬁcates underestimated the impact
of several major illnesses.
CONCLUSIONS: Healthcare costs at the end of life vary
widely by age and the number and type of chronic ill-
nesses in the year prior to death. Cause of death listed on
death certiﬁcates does not accurately reﬂect the impact of
chronic illness on terminal costs.
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OBJECTIVES: This study examines screening alternatives
for detection of hereditary hemochromatosis (HH). The
objectives included: (1) To evaluate three screening alter-
natives (no screening, phenotype screening, and genotype
screening) in a cost-effectiveness analysis for HH; and, (2)
To serve as a model for genetic diseases.
METHODS: The decision analysis using Data 3.5 soft-
ware was conducted for both cost-effectiveness and cost-
utility analyses. A hypothetical cohort of 10,000 white
males between thirty and thirty-nine years old was the
identiﬁed as the model population because of its high HH
prevalence rate. Each screening alternative correlated 
to a decision tree branch, which further subdivided into
branches depending upon treatment decisions. The costs
data were conservatively estimated using 2001 United
States Medicare charge data. Testing protocols were
based on established methods previously used in a cost-
effectiveness study by Adams and Valberg in 1999. The
utility values were estimated using experts’ judgments on
the Health Utilities Index.
RESULTS: The results of the cost-effectiveness analysis
indicated that genotype testing was the dominant strat-
egy. The marginal cost-effectiveness of genetic testing
found that an extra $219.85 per case would identify
another thirteen cases. A sensitivity analysis found the
genetic testing cost as the threshold value. The cost-utility
analysis, using quality-adjusted life years (QALY) as a
measure of effectiveness, indicated that genotype testing
was the dominant strategy. The marginal cost/QALY
found that an additional $85.48 per case identiﬁed 10
new cases.
CONCLUSIONS: Genetic testing for HH represents an
opportunity for widespread screening. The high preva-
lence rate and beneﬁt of early diagnosis and treatment
make HH an ideal screening target. The infrastructure for
genetic testing must be built before widespread screening
could occur; thus, the policy-makers and insurance com-
panies should be educated about cost-effectiveness studies
which demonstrate the merits of detecting genetic diseases
prior to symptom manifestation.
